- Founded as Hayashibara Shoten (a starch syrup manufacturer) in Okayama, Japan.
- Hayashibara Shoten was incorporated on July 10.
- Developed the two-step (acid and malt) starch-conversion method for starch syrup production.
- Increased daily output of starch syrup to 40 metric tons.
- The company's name was changed from Hayashibara Shoten to Hayashibara Co., Ltd.
- Entire factory destroyed by an air raid.
- Rebuilt factory and resumed operations.
- Established Japanese Research Institute for Photosensitizing Dyes Co., Ltd.
- Increased the daily output of syrup to 150 metric tons, making Hayashibara the largest starch syrup manufacturer in Japan.
- Japanese Research Institute for Photosensitizing Dyes Co., Ltd. launched pharmaceutical products "Lumin A-50 γ tablet" and "Lumin A-100 γ tablet" containing a photosensitizing dye as an active ingredient.
- Industrialized the enzymatic production method of glucose from starch.
- Constructed a new factory in Okayama, Japan to process 180 metric tons of glucose daily.
- Established Hayashibara Shoji, Inc. (Trading Company) for expanding sales of starch syrup and glucose.
- Developed the enzymatic saccharification method for maltose.
- Discovered Isoamylase, a debranching enzyme that acts on the branching parts of starch molecules (amylopectin).
- Developed the production method for high purity maltose (not less than 99%).
Developed the production method for maltitol and licensed it to Anic S.p.A. in 1979.
- Developed the production method for glycosylsucrose syrup incorporating the characteristics of sucrose with other properties.
- Established Hayashibara Biochemical Laboratories, Inc.
- Developed the production method for cyclodextrin (licensed it to Ensuiko Sugar Refining Co., Ltd. in 1987 and to Novo Nordisk in 1998).
- Developed the production method for "PULLULAN", a polysaccharide thickener and edible film matrix.
- Completed Okayama Plant II in Okayama, Japan.
Launched "SUNMALT", food grade maltose powder.
- Began manufacturing "PULLULAN" in a new production facility at Okayama Plant II.
- Developed the production method for glucosyl stevia (licensed it to Toyo Sugar Refining Co., Ltd. in 1979 and to Sanyo-Kokusaku Pulp Co., Ltd. in 1982).
- Developed the in vivo proliferation method using human cells for the industrial-scale manufacturing of bioactive substances.
- Developed the production method for lactosucrose, an oligosaccharide with unique characteristics.
- Completed Fujisaki Institute in Okayama, Japan.
Developed the production method for anhydrous crystalline maltitol (licensed it to Towa Chemical Industry Co., Ltd. and Anic S.p.A. in 1982 and to Roquette Frères in 1992).
- The Company marked its 100th anniversary.
- Completed Fujisaki Cell Center in Okayama, Japan.
- Developed the production method for maltotetraose,a starch syrup with pleasant sweetness and reduced off-notes.
Completed Kibi Pharmaceutical Plant & Institute in Okayama, Japan.
- Was approved to produce bulk interferon-α, and the interferon-α as a therapeutic drug.
Commercial products were launched by Otsuka Pharmaceutical Co., Ltd. and Mochida Pharmaceutical Co., Ltd.
Japanese Research Institute for Photosensitizing Dyes Co., Ltd. completed Fujita Plant in Okayama, Japan.
Their Imperial Highnesses the Crown Prince Akihito and the Crown Princess Michiko (presently the Emperor Emeritus and the Empress Emeritus of Japan) honored Kibi Pharmaceutical Plant with a royal visit.
- Developed the production method for ascorbic acid 2-glucoside, a stable vitamin C.
Developed the production method for glucosyl hesperidin, a citrus-derived polyphenol.
Developed the production method for glucosyl rutin and licensed it to Toyo Sugar Refining Co., Ltd.
- Was approved for the extended application of interferon-α drug, OIF, to treat hepatitis B. The commercial product launched by Otsuka Pharmaceutical Co., Ltd.
Developed the production method for maltosyltrehalose, a carbohydrate with low reducing potential.
- Developed the production method for trehalose from starch.
- Discovered Interleukin-18 (IL-18), a new bioactive substance.
Launched "TREHA", a high purity trehalose.
Launched "AA2G", a stable vitamin C for cosmetic use.
- Won a patent dispute on biotechnology patent with Roche, a company based in Switzerland.
Entered into an exclusive supply contract with the U.S. firm Warner-Lambert Company to supply "PULLULAN" for use in a breath freshening film.
Japanese Research Institute for Photosensitizing Dyes Co., Ltd. completed Fujita Pharmaceutical Plant in Okayama, Japan.
- Merged Japanese Research Institute for Photosensitizing Dyes Co. and other companies into Hayashibara Biochemical Labs., Inc.
- Their Majesties the Emperor and Empress of Japan (presently the Emperor Emeritus and the Empress Emeritus) honored Fujisaki Institute with a royal visit.
Obtained US FDA GRAS status with "No Questions Letter" for Trehalose U.S.
- Entered a global license and supply agreement with Pfizer Inc. for oral applications of "PULLULAN" .
- Obtained US FDA GRAS status with "No Questions Letter" for "PULLULAN".
Jointly developed a hard capsule made from "PULLULAN" with Capsugel.
- Launched "HALLODEX", a multi-function starch based syrup.
Launched "MG-60", a carbohydrate based material for cosmetics.
- Completed Okayama Functional Saccharide Plant in Okayama, Japan.
- Hayashibara Co., Ltd., Hayashibara Shoji, Inc., Hayashibara Biochemical Labs., Inc., and Taiyo Estate Co., Ltd. filed for application of the Corporate Rehabilitation Law.
- Tokyo District Court approved the reorganization plan filed in 2011.
Hayashibara Co., Ltd. merged Hayashibara Shoji, Inc., and Hayashibara Biochemical Labs., Inc.
NAGASE & CO., LTD. made Hayashibara Co., Ltd. a wholly owned subsidiary.
Received the court decision of completion of the reorganization proceedings.
Okayama Functional Saccharide Plant earned FSSC 22000 certification.
- Headquarters, three plants, and two departments earned ISO 9001 certification.
- Completed the S Facility of Okayama Functional Saccharide Plant in Okayama, Japan.
Completed the New Okayama plant Ⅰin Okayama, Japan.
Launched "Fibryxa" (Main cmponent：Isomaltodextrin), a water soluble dietary fiber.
- Obtained US FDA GRAS status with "No Questions Letter" for Isomaltodextrin (Main component of "Fibryxa").
- Finalized a long-term agreement with Lonza Ltd. in order to expand the market of capsules made from Pullulan.
- Launched “Glucosyl Naringin”, a citrus-derived aging-care cosmetic ingredient.
Completed the new facilities to produce Pullulan and various enzymes at Okayama Plant II.
Commenced the industry-academia partnership with Okayama University to support the Sustainable Development Goals (SDGs) through new technologies.